News|Articles|November 4, 2026

Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule

A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed COINS Act biotechnology restrictions are too broad, while the National Security Commission on Emerging Biotechnology backs the move. Comments are due December 7, 2026.

Policy experts and industry groups are pressing the US Department of the Treasury to narrow its proposal to add biotechnology to the Outbound Investment Security Program, arguing that it would sweep in commercial drug development. The proposed rule, issued October 22, 2026, under the Comprehensive Outbound Investment National Security (COINS) Act, would prohibit certain US investments in biotechnology companies in China and other countries of concern.¹

Related to this article

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

November 3rd, 2026

FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies

Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.

Stainless steel pilot-scale bioreactor with a sight glass, tubing, and valves next to a control cabinet with a touchscreen and peristaltic pumps. | Image Credit: © Grispb - stock.adobe.com

November 3rd, 2026

Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity

The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.

3D illustration of orange-yellow antibodies binding to Y-shaped receptors on a blue cell surface against a dark background, with another antibody floating in the distance. | Image Credit: © Tatiana Shepeleva - stock.adobe.com

November 2nd, 2026

Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates

The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.

Grid of black-and-white brain CT scans with a blue tint, showing cross-sections of the head from the top, front, and side. | Image Credit: © photoprofi30 - stock.adobe.com

November 2nd, 2026

FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review

FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.

Human Respiratory System Lungs Anatomy | Image credit: © magicmine - © magicmine - stock.adobe.com

November 2nd, 2026

FDA Grants Accelerated Approval to Inovio DNA Immunotherapy for RRP

Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.

Close-up of two prefilled syringes on a light blue surface, one in focus with a clear barrel and exposed needle and a labeled syringe blurred in the background. | Image Credit: © omar - stock.adobe.com

October 30th, 2026

FDA Approves Sun Pharma’s Ilumya for Active Psoriatic Arthritis

The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.

fda on paper texture | Image credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com

October 29th, 2026

FDA Draft Guidance Outlines BLA Path for Individualized Gene Editing

The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.

Various of international money coin and banknote with blurred hourglass in the background. Time investment with currency exchange concept. Focus on dollar banknote. | Image credit: © zephyr_p - © zephyr_p - stock.adobe.com

November 3rd, 2026

Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India

Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.